Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940805 | 0.79 | MAPT (0.44) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL1270651 | 0.78 | ESR1 (0.42) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL9225762 | 0.78 | ESR1 (0.42) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL12191013 | 0.76 | ESR1 (0.41) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL4908749 | 0.75 | ESR1 (0.33) | ESR1ESR2MAPT | |
| SCHEMBL9339400 | 0.74 | ESR1 (0.39) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL7935088 | 0.74 | ESR1 (0.44) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL10427763 | 0.74 | NR1H2 (0.41) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL1270667 | 0.74 | ESR1 (0.39) | ESR1ESR2MAPTNR1H2NR1H3 | |
| SCHEMBL7517705 | 0.74 | ESR1 (0.39) | ESR1ESR2MAPTNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643706-B1 | MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | claimed |
| US-9896473-B2 | Thiol compounds and the use thereof for the synthesis of modified oligonucleotides | ETABLISSEMENT FRANCAIS DU SANG (FR) | 2018-02-20 | — | — | US | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| EP-2834253-B1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-03-29 | — | — | EP | claimed |
| US-20150158964-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2015-06-11 | — | — | US | claimed |
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2010-12-23 | — | — | US | claimed |
| EP-2088865-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | Jina Pharmaceuticals Inc. (US) | 2009-08-19 | — | — | EP | claimed |
| WO-2008058156-A9 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-12-04 | — | — | WO | claimed |
| EP-1986607-A2 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | Neopharm, Inc. (US) | 2008-11-05 | — | — | EP | claimed |
| US-6172217-B1 | SULFURIZATION OF PHOSPORDIAMIDITE; DEBLOCKING | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | claimed |
| US-6103891-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-15 | — | — | US | claimed |
| EP-0948512-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| EP-0948514-A1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| US-5955600-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1998029427-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998029429-A1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158964-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | TST, APEX1, TMT1A | ESR1 4596/4885ESR2 4257/4885MAPT 1441/4885 |
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | PHOSPHO1, SGMS1, SGMS2 | ESR1 4835/4885ESR2 4861/4885MAPT 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.